Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SRRK, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Apitegromab FDA approved Sep 2026 · Isembyld |
Spinal Muscular Atrophy | Phase 3 · NCT05626855 | Active not recruiting |
| Risdiplam | Spinal Muscular Atrophy | Phase 2 · NCT07047144 | Recruiting |
| SRK-015 | Spinal Muscular Atrophy | Phase 2 · NCT03921528 | Completed |
| anti-PD-(L)1 antibody therapy | Cancer | Phase 1 · NCT04291079 | Completed |
| Linavonkibart (SRK-181) | Cancer | Phase 1 · NCT04291079 | Completed |
| SRK-439 | Healthy | Phase 1 · NCT07444294 | Recruiting |
Also used in these trials (approved or third-party drugs, not SRRK's own candidates): Nusinersen, Tirzepatide.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SRRK holds $492.1M in cash and short-term investments (as of Jun 30, 2026) and burns about $76.2M/quarter from operations, an estimated runway of 19.4 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 47 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SRRK files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR, LLC | Institution (13F) | 17,995,241 | 14.78% | 2026-06-30 |
| Invus Global Management, LLC 10% owner |
Insider | 10,825,013 | 8.89% | 2025-12-11 |
| Invus Public Equities, L.P. | 5%+ holder (13G) | 9,575,013 | 7.86% | 2026-06-30 |
| Siren, L.L.C. | Institution (13F) | 9,575,013 | 7.86% | 2026-06-30 |
| Blackrock Inc. | Institution (13F) | 9,494,084 | 7.80% | 2026-06-30 |
| Srinivas Akkaraju Director · +4,310 options |
Insider | 6,925,623 | 5.69% | 2026-06-04 |
| Samsara BioCapital, LLC | Institution (13F) | 6,897,652 | 5.66% | 2026-06-30 |
| T. Rowe Price Associates, Inc. | Institution (13G, 5%+) | 6,206,044 | 5.10% | 2026-03-31 |
| Orbis Allan Gray Ltd | Institution (13F) | 5,933,533 | 4.87% | 2026-06-30 |
| Wellington Management Group LLP | Institution (13G, 5%+) | 5,759,428 | 4.73% | 2025-12-31 |
| Vanguard Capital Management LLC | Institution (13F) | 4,767,880 | 3.91% | 2026-06-30 |
| State Street Corporation | Institution (13F) | 4,728,681 | 3.88% | 2026-06-30 |
Share count 121,785,282 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-24 filed 2026-09-25 |
Woods Keith |
Gift (G) | 48,034 | – | 572,021 |
| 2026-09-21 filed 2026-09-23 |
Hallal David |
Gift (G) | 36,652 | – | 1,602,382 |
| 2026-07-01 filed 2026-07-06 |
Burow Kristina |
Sale (S) | 2,105 | $53.49 | 115,605 |
| 2026-07-01 filed 2026-07-06 |
Gilman Michael |
Sale (S) | 1,346 | $53.54 | 60,709 |
| 2026-07-01 filed 2026-07-06 |
Gilman Michael |
Sale (S) | 1,155 | $54.23 | 59,554 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-09-11 | ISEMBYLD | BLA | +6.9% | -0.5% | -12% |
| 2026-03-03 | — | BLA | -3.2% | +1.9% | +1.7% |
| 2025-09-22 | apitegromab | BLA | -10.4% | +5.6% | +25.7% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SRRK and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →